Literature DB >> 6118906

What is the best maintenance dose of neuroleptics in schizophrenia?

R J Baldessarini, J M Davis.   

Abstract

Short-term use of neuroleptics as well established for many psychotic disorders; details about long-term use remain less clear. Most long-term studies involved patients diagnosed as chronic schizophrenics and used phenothiazines; responses, dose requirements, and probably diagnosis were highly heterogeneous. Data from controlled studies permitting estimates of the equivalent dose of chlorpromazine to be plotted vs. reduction of relapse rates revealed no significant dose effect between 100 and over 2,000 (median = 310) mg/kg day, no mean difference in outcome at doses above vs. below 310 mg, and a mean relapse of placebo of only 54%. Since maintenance requirements for some patients may be low, the use of minimum effective doses is encouraged and may limit risks of late toxicity, as further long-term studies of the effect of dose are undertaken.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6118906     DOI: 10.1016/0165-1781(80)90028-1

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  10 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

Review 2.  Pharmacological treatment of patients with schizophrenia. Past and present problems and potential future therapy.

Authors:  D A Johnson
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

3.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

4.  Low dose maintenance medication for schizophrenia.

Authors:  R Manchanda; S R Hirsch
Journal:  Br Med J (Clin Res Ed)       Date:  1986-08-30

Review 5.  Patient compliance with drug therapy in schizophrenia. Economic and clinical issues.

Authors:  E Lindström; K Bingefors
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

6.  Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective.

Authors:  S P Segal; D Cohen; S R Marder
Journal:  Am J Public Health       Date:  1992-06       Impact factor: 9.308

7.  A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia.

Authors:  D J King; M Blomqvist; S J Cooper; M M Doherty; M J Mitchell; R C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Circadian changes in behavioral effects of haloperidol in rats.

Authors:  A Campbell; R J Baldessarini
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.

Authors:  Heidi Taipale; Antti Tanskanen; Jurjen J Luykx; Marco Solmi; Stefan Leucht; Christoph U Correll; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

10.  Polygenic pleiotropy and potential causal relationships between educational attainment, neurobiological profile, and positive psychotic symptoms.

Authors:  Yen-Feng Lin; Chia-Yen Chen; Dost Öngür; Rebecca Betensky; Jordan W Smoller; Deborah Blacker; Mei-Hua Hall
Journal:  Transl Psychiatry       Date:  2018-05-16       Impact factor: 6.222

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.